Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery,
radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the …

Metastatic triple negative breast cancer (TNBC) has an aggressive phenotype with a
predilection for visceral organs and brain. Best responses to chemotherapy are …

The limited efficacy of immune checkpoint inhibitor treatment in triple-negative breast cancer
(TNBC) patients is attributed to sparse or unresponsive tumor-infiltrating lymphocytes, but …

Triple-negative breast cancer (TNBC), a highly metastatic breast cancer subtype, has limited
treatment options. While a small number of patients attain clinical benefit with single-agent …

Studies have shown that the presence of tumor infiltrating lymphocytes (TILs) in Triple
Negative Breast Cancer (TNBC) is associated with better prognosis. However, the molecular …

The period between" successful" treatment of localized breast cancer and the onset of
distant metastasis can last many years, representing an unexploited window to eradicate …

Quantitative systems pharmacology (QSP) modeling is an emerging mechanistic
computational approach that couples drug pharmacokinetics/pharmacodynamics and the …

Immunotherapy is currently approved for a subset of patients diagnosed with advanced triple
negative breast cancer (TNBC), based on the phase III randomized controlled trial …

Somatic mutation-derived neoantigens are associated with patient survival in breast and
ovarian cancer. These neoantigens are targets for cancer, as shown by the implementation …

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that has few
effective treatment options due to its lack of targetable hormone receptors. Whilst the degree …